Fluorine-18 AV 1451 positron emission tomography in patients with non-Alzheimer's disease neurodegenerative syndromes associated with tau-positive or tau-negative pathology

Trial Profile

Fluorine-18 AV 1451 positron emission tomography in patients with non-Alzheimer's disease neurodegenerative syndromes associated with tau-positive or tau-negative pathology

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Flortaucipir F 18 (Primary)
  • Indications Chronic brain damage; Corticobasal degeneration; Dementia; Progressive supranuclear palsy
  • Focus Diagnostic use
  • Most Recent Events

    • 21 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top